Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases. Alios has an innovative team of scientists who have discovered and developed a number of antiviral agents against viral pathogens of public health concern including HCV, influenza and respiratory syncytial virus (RSV) as well as other chronic, acute and emerging viruses. The company has developed proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections. The nucleoside approach has the advantage over other strategies as these agents can inhibit divergent variants of many viruses resulting in therapeutics that could be used to treat existing infections as well as emerging viruses, including H5N1 Bird Flu or Pandemic H1N1 Swine Flu. Alios has two nucleoside analogs (ALS-2200 and ALS-2158) in Phase I clinical development for the treatment of chronic hepatitis C. Under a 2011 collaborative research and development agreement, the anti-HCV nucleoside analogs are being developed in partnership with Vertex Pharmaceuticals. This partnership could result in payments to Alios of up to $1.9 billion not including royalty payments on sales.
Alios also has nucleoside analogs that are active against RSV, a disease that infects millions of children and adults each year. An anti-RSV nucleoside analog is on track to enter clinical development by the end of 2012. The company is also pursuing nucleoside analogs for influenza, and in addition has licensed technology targeting influenza viruses from Versitech Ltd, and plans to begin clinical development of an anti-Influenza compound in 2013. Alios BioPharma completed a $32 million Series A financing in December of 2008 and is currently self funding through revenues received under the Vertex agreement.